Document is current
Any future updates will be listed below
-
Authors
Cheng, Monica https://orcid.org/0000-0002-8839-677X
Causa Andrieu, Pamela https://orcid.org/0000-0003-0411-3072
Kim, Tae-Hyung https://orcid.org/0000-0002-0333-8475
Gangai, Natalie https://orcid.org/0000-0003-0603-7165
Sonoda, Yukio https://orcid.org/0000-0001-9684-5291
Hricak, Hedvig https://orcid.org/0000-0003-2240-9694
Lakhman, Yulia https://orcid.org/0000-0003-3626-4502
Vargas, Hebert A. https://orcid.org/0000-0003-1169-133X
Woo, Sungmin https://orcid.org/0000-0001-8459-8369
-
Funding
Funding for this research was provided by:
NIH/NCI (Cancer Center Support Grant P30 CA008748)
- License Information
-
More Information
Article History
Received: 2 July 2022
Revised: 15 September 2022
Accepted: 16 September 2022
First Online: 29 September 2022
Declarations
:
: (1) Since May 2017, Dr. Hricak has served on the Board of Directors of Ion Beam Applications (IBA), a publicly traded company, and she receives annual compensation for her service. Dr. Hricak is also a member of the External Advisory Board of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins; the International Advisory Board of the University of Vienna, Austria; the Scientific Committee of the DKFZ (German Cancer Research Center), Germany; the Board of Trustees the DKFZ; and the Board of Directors of Paige. She does not receive financial compensation for any of these roles. (2) Yulia Lakhman holds ownership of equity interests in Y-mAbs Therapeutics, Inc. She also consults for Calyx and receives compensation for her service but unrelated to this paper. (3) The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
